This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore contentEventsMaterialsVideosLet's connectLet's ConnectPfizer medical information

Menu

Close

AboutAboutExtended CoveragePK and PD ProfileGood Safety ProfileGuidelines and RecommendationsDosingRecommended DosageAdultsSpecial PopulationEfficacyIntra-abdominal InfectionRisk factorClinical efficacyUrinary Tract InfectionRisk factorClinical efficacyRespiratory Tract InfectionResistance rateImpactClinical efficacyFebrile NeutropeniaRisk factorTreatmentClinical efficacySafetyClinical & Scientific DataSupport & ResourcesSupport & ResourcesClinical UpdatesPrescribing InformationVideosWebinarsExplore Materials

Indication: Monotherapy – Sulbactam/Cefoperazone is indicated for the treatment of the following infections when caused by susceptible organisms: Respiratory tract infections, urinary tract infections (upper and lower), intra-abdominal infections, septicaemia, meningitis, skin and soft tissue infections, bone and joint infections, endometritis and other infections in the genital tract. MAGNEX® FORTE is indicated for a specific subset of patients (patients with immunocompromised febrile neutropenic cancer, patients who have undergone a bone marrow transplant).1
Clinical Efficacy & Tolerability

Antimicrobial activity of cefoperazone/sulbactam

  

Cefoperazone/Sulbactam shows antimicrobial activity against ESBL-producing E. coli and K. pneumoniae organisms1

  

Cefoperazone/Sulbactam in patients with VAP due to CRAB strains

  

Adjunctive therapy with CEP-SUL+ had lower mortality rates and resource utilisation compared with CEP-SUL- in patients with VAP due to CRAB strains3

  • Thirty-day and in-hospital mortality rates for CEP-SUL+ were significantly lower than CEP-SUL− with values of 35%, 39% and 61%, 68%, for CEP-SUL+ and CEP-SUL−, respectively3
     
  • The survival rate for CEP-SUL+ was significantly higher compared with CEP-SUL− (P<0.001)3
     
  • The number of hospital days, ventilator days since diagnosis of VAP and hospital costs were lower for CEP-SUL+3 

  

Adapted from Kanchanasuwan S, et al. 2021.

  

BL/BLIs in infections with ESBL-producing strains

  • In children with high risk of ESBL-producing UTI pathogens or in children with severe sepsis/septic shock, empiric therapy should be initiated with BL/BLI combinations (piperacillin-tazobactam/cefoperazone-sulbactam) or carbapenems4
     
  • In a study which constituted 75.7% of patients with ESBL-producing microbes, the strains were sensitive carbapenems, piperacillin-tazobactam and cefoperazone-sulbactam. The organisms had a 3% resistance to imipenem and 41%, 29.5% and 30.3% resistance to amikacin, piperacillin-tazobactam and cefoperazone-sulbactam, respectively5
The SENTRY Antimicrobial Surveillance Programme dataThe SENTRY antimicrobial surveillance programme data: Cefoperazone/Sulbactam was among the most active compounds against gram-negative organisms from Europe, APAC and Latin.6

Cefoperazone/Sulbactam continues to demonstrate good in vitro activity against Enterobacterales and P. aeruginosa isolates from the APAC region.6
  • In all, 82% to 94.4% of Enterobacterales were susceptible to cefoperazone/sulbactam at ≤16 mg/L6
     
  • In all, 59.5% to 84.6% of P. aeruginosa were susceptible to cefoperazone/sulbactam at ≤16 mg/L6

Adapted from Sader HS, et al. 2020.

Adapted from Sader HS, et al. 2020.

*In patients using cefoperazone/sulbactam with or without combination with antimicrobial drugs, n=60. Combinations used were cefoperazone/sulbactam combined with minocycline, levofloxacin and meropenem.

AE, adverse event; APAC, Asia-Pacific; BL, beta-lactam; BLI, beta-lactamase inhibitor; CDAD, Clostridium difficile-associated diarrhoea; CEP-SUL−, patients who did not receive cefoperazone/sulbactam; CEP-SUL+, patients who received cefoperazone/sulbactam; CI, confidence interval; CRAB, carbapenem-resistant Acinetobacter baumannii; E-EU, Eastern Europe and Mediterranean; ESBL, extended-spectrum beta-lactamase; HAP, hospital-acquired pneumonia; LATAM, Latin America; RCT, randomised controlled trial; RR, risk ratio; VAP, ventilator-associated pneumonia; UTI, urinary tract infection; W-EU, Western Europe.

References:

Gupta D, Agarwal R, Aggarwal AN, et al. Guidelines for diagnosis and management of community- and hospital-acquired pneumonia in adults: joint ICS/NCCP(I) recommendations. Lung India. 2012;29(suppl 2):S27-S62.​​​​​​​​​​​​​​​​​​​​​Xia J, Zhang D, Xu Y, Gong M, Zhou Y, Fang X. A retrospective analysis of carbapenem-resistant Acinetobacter baumannii-mediated nosocomial pneumonia and the in vitro therapeutic benefit of cefoperazone/sulbactam. Int J Infect Dis. 2014;23:90-93.​​​​​​​Kanchanasuwan S, Kositpantawong N, Singkhamanan K, et al. Outcomes of adjunctive therapy with intravenous cefoperazone-sulbactam for ventilator-associated pneumonia due to carbapenem-resistant Acinetobacter baumannii. Infect Drug Resist. 2021;14:1255-1264.​​​​​​​Singhal T. “Rationalization of empiric antibiotic therapy” - a move towards preventing emergence of resistant infections. Indian J Pediatr. 2020;87(11):945-950.​​​​​​​Vijayganapathy S, Karthikeyan VS, Mallya A, Mythri KM, Visvanatha R, Keshavamurthy R. Antimicrobial resistance patterns in a tertiary care nephro-urology center in South India. J Integr Nephrol Androl. 2018;5:93-99.Sader HS, Carvalhaes CG, Streit JM, Castanheira M, Flamm RK. Antimicrobial activity of cefoperazone-sulbactam tested against gram-negative organisms from Europe, Asia-Pacific, and Latin America. Int J Infect Dis. 2020;91:32-37.​​​​​​​​​​​​​​Shiber S, Yahav D, Avni T, Leibovici L, Paul M. β-Lactam/β-lactamase inhibitors versus carbapenems for the treatment of sepsis: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2015;70(1):41-47. 


Please click the Prescribing Information link to view the safety and adverse events information of MAGNEX®.
For the use only of registered medical practitioner, or a hospital or a laboratory.


PP-MGX-IND-0555 June 2022
Clinical & Scientific Data

About

Cefoperazone/Sulbactam: ​​​​​​​Extended coverage with β-lactamase inhibition​​​​​​

Learn more


Dosing

Recommended dosage in adult ​​​​​​and special population​​​​​​​

Learn more


Efficacy

Cefoperazone/Sulbactam is recommended as an effective and well-tolerated antibiotic

Review efficacy profile


PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out
 
These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.
​​​​​​​
Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
 
PP-MGX-IND-0555

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

Copyright © 2023 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
For the use only of Registered medical practitioners* or a Hospital or a Laboratory

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.

 

If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered medical practitioner*, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-DOL-IND-0251 18 JAN 2023Yes No
You are now leaving PfizerPro website
​
​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?
PP-DOL-IND-0251 18 JAN 2023